Bavarian Nordic completes rights issue
27 May 2011
Download pdf
Not for release, publication
or distribution in the United States, Canada, Australia or
Japan
This announcement does not constitute
an offer to sell or the solicitation of an offer to buy the
securities of Bavarian Nordic A/S (the "Securities") in the United
States or in any other jurisdiction. The Securities may not be
offered or sold in the United States absent registration or an
exemption from registration under the U.S. Securities Act of 1933,
as amended. The issuer of the Securities has not registered, and
does not intend to register, any portion of the Offering in the
United States or in any jurisdiction outside Denmark and the United
Kingdom, and does not intend to conduct a public offering of the
Securities in the United States or in any other jurisdiction
outside Denmark and the United Kingdom. Copies of this announcement
are not being made and may not be distributed or sent into the
United States, Canada, Australia or Japan.
This announcement is only being
distributed to, and is only directed at, persons in the United
Kingdom that are qualified investors, as that term is defined in
the Prospectus Directive, that are also (i) "investment
professionals" falling within Article 19(5) of the Financial
Service and Markets Act 2000 (Financial Promotion) Order 2005 (the
"Order") or (ii) "high net worth entities" and other persons to
whom it may lawfully be communicated, falling within the meaning of
Article 49(2)(a) to (d) of the Order (all such persons being
"relevant persons"). The securities of Bavarian Nordic A/S (the
"Securities") are only available to relevant persons and any
invitation, offer or agreement to subscribe, purchase or otherwise
acquire such Securities will be engaged in only with relevant
persons. Any person who is not a relevant person should not act or
rely on this announcement or any of its content.
Kvistgård, Denmark, May 27, 2011 - Bavarian
Nordic A/S (NASDAQ OMX: BAVA) today completed an offering of shares
of up to 12,962,052 new shares each of a nominal value of DKK 10
with pre-emptive rights to the Company's existing shareholders (the
"Offering"). In the Offering, 12,918,593 new shares with a nominal
value of DKK 10 each were subscribed, corresponding to 99.7 % of
the offered shares.
The new shares were subscribed at DKK 54 per share with a
nominal value of DKK 10, resulting in gross proceeds to Bavarian
Nordic of approximately DKK 698 million, equivalent to net proceeds
of approximately DKK 653 million after deduction of expenses
related to the Offering.
The new shares are expected to be admitted to trading and
official listing on NASDAQ OMX Copenhagen A/S on 31 May 2011 under
the same ISIN code as Bavarian Nordic's existing shares
(DK0015998017).
Following registration of the 12,918,593 new shares with a
nominal value of DKK 10 each, Bavarian Nordic's nominal share
capital will be DKK 258,806,450 corresponding to 25,880,645 shares
with a nominal value of DKK 10 each. Each share with a nominal
value of DKK 10 carries one vote.
The new shares have the same rights as the Company's existing
shares.
Following the Offering, the Company expects its year-end cash
preparedness to be in the level of DKK 525 million. The Company's
expectations for full-year revenue and result remain as previously
announced.
Anders Hedegaard, President & CEO comments: "We are
delighted to announce a successful result of our offering, which
has attracted a lot of positive attention from both new and
existing investors, adding several new and reputable international
healthcare investors to our shareholder base. With the completion
of the offering, we look forward to a promising period for Bavarian
Nordic. Our capital preparedness has been strengthened, enabling us
to pursue the independent development of PROSTVAC® and thus
initiate the Phase 3 trial in the second half of 2011 as planned.
At the same time we have secured both the progress of the project,
as well as a strong position in the further discussions with
potential partners by maintaining the value of PROSTVAC® in the
company."
Contact:
Anders Hedegaard, President & CEO.
Phone: +45 23 20 30 64